newsfilter
← Latest News
GlobeNewswire·

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

  • BioNexus Gene Lab Corp. (NASDAQ: BGLC) participated in the 2026 China–Malaysia Economic Cooperation Outlook Forum held on May 21, 2026, in Kuala Lumpur.
  • CEO Sam Tan advocated for a Malaysia–China precision healthcare corridor to shift collaboration from trade to co-development, clinical validation, commercialization, capital markets engagement, & regional access.
  • Tan identified Malaysia's role as an ASEAN execution hub for clinical validation, regulatory navigation, laboratory deployment, healthcare data development, & regional commercialization of Chinese biotechnology innovation.
  • The company emphasized a shift in precision healthcare from late-stage treatment to early detection, continuous monitoring, personalized intervention, & AI-assisted clinical insight.
  • BioNexus highlighted its cross-border commercialization model involving Fidelion Diagnostics Pte. Ltd. & the VitaGuard™ MRD platform to pair China-origin innovation with Malaysia-based capabilities & public-company discipline.
  • Strategic pillars for Malaysia–China collaboration include accelerated clinical validation for China-origin precision oncology & liquid biopsy technologies, targeted biotechnology infrastructure development, & AI-integrated healthcare deployment compliant with regional data sovereignty.
  • BioNexus aims to leverage its Nasdaq listing to provide public-market rigor, transparency, & partner credibility to support scalable healthcare platforms across Asia & the United States.
  • The company seeks to position Malaysia as a bridge between Chinese biotechnology innovation & ASEAN healthcare needs through platforms for precision diagnostics, clinical validation, regional manufacturing, & affordable patient access.